A randomized clinical trial comparing low-fat with precision nutrition-based diets for weight loss: impact on glycemic variability and HbA1c.
MAGE
diabetes
glycemic variability
low-fat diet
personalized nutrition
precision nutrition
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
06
2022
revised:
16
05
2023
accepted:
23
05
2023
pmc-release:
14
06
2024
medline:
7
8
2023
pubmed:
27
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Recent studies have demonstrated considerable interindividual variability in postprandial glucose response (PPGR) to the same foods, suggesting the need for more precise methods for predicting and controlling PPGR. In the Personal Nutrition Project, the investigators tested a precision nutrition algorithm for predicting an individual's PPGR. This study aimed to compare changes in glycemic variability (GV) and HbA1c in 2 calorie-restricted weight loss diets in adults with prediabetes or moderately controlled type 2 diabetes (T2D), which were tertiary outcomes of the Personal Diet Study. The Personal Diet Study was a randomized clinical trial to compare a 1-size-fits-all low-fat diet (hereafter, standardized) with a personalized diet (hereafter, personalized). Both groups received behavioral weight loss counseling and were instructed to self-monitor diets using a smartphone application. The personalized arm received personalized feedback through the application to reduce their PPGR. Continuous glucose monitoring (CGM) data were collected at baseline, 3 mo and 6 mo. Changes in mean amplitude of glycemic excursions (MAGEs) and HbA1c at 6 mo were assessed. We performed an intention-to-treat analysis using linear mixed regressions. We included 156 participants [66.5% women, 55.7% White, 24.1% Black, mean age 59.1 y (standard deviation (SD) = 10.7 y)] in these analyses (standardized = 75, personalized = 81). MAGE decreased by 0.83 mg/dL per month for standardized (95% CI: 0.21, 1.46 mg/dL; P = 0.009) and 0.79 mg/dL per month for personalized (95% CI: 0.19, 1.39 mg/dL; P = 0.010) diet, with no between-group differences (P = 0.92). Trends were similar for HbA1c values. Personalized diet did not result in an increased reduction in GV or HbA1c in patients with prediabetes and moderately controlled T2D, compared with a standardized diet. Additional subgroup analyses may help to identify patients who are more likely to benefit from this personalized intervention. This trial was registered at clinicaltrials.gov as NCT03336411.
Sections du résumé
BACKGROUND
Recent studies have demonstrated considerable interindividual variability in postprandial glucose response (PPGR) to the same foods, suggesting the need for more precise methods for predicting and controlling PPGR. In the Personal Nutrition Project, the investigators tested a precision nutrition algorithm for predicting an individual's PPGR.
OBJECTIVE
This study aimed to compare changes in glycemic variability (GV) and HbA1c in 2 calorie-restricted weight loss diets in adults with prediabetes or moderately controlled type 2 diabetes (T2D), which were tertiary outcomes of the Personal Diet Study.
METHODS
The Personal Diet Study was a randomized clinical trial to compare a 1-size-fits-all low-fat diet (hereafter, standardized) with a personalized diet (hereafter, personalized). Both groups received behavioral weight loss counseling and were instructed to self-monitor diets using a smartphone application. The personalized arm received personalized feedback through the application to reduce their PPGR. Continuous glucose monitoring (CGM) data were collected at baseline, 3 mo and 6 mo. Changes in mean amplitude of glycemic excursions (MAGEs) and HbA1c at 6 mo were assessed. We performed an intention-to-treat analysis using linear mixed regressions.
RESULTS
We included 156 participants [66.5% women, 55.7% White, 24.1% Black, mean age 59.1 y (standard deviation (SD) = 10.7 y)] in these analyses (standardized = 75, personalized = 81). MAGE decreased by 0.83 mg/dL per month for standardized (95% CI: 0.21, 1.46 mg/dL; P = 0.009) and 0.79 mg/dL per month for personalized (95% CI: 0.19, 1.39 mg/dL; P = 0.010) diet, with no between-group differences (P = 0.92). Trends were similar for HbA1c values.
CONCLUSIONS
Personalized diet did not result in an increased reduction in GV or HbA1c in patients with prediabetes and moderately controlled T2D, compared with a standardized diet. Additional subgroup analyses may help to identify patients who are more likely to benefit from this personalized intervention. This trial was registered at clinicaltrials.gov as NCT03336411.
Identifiants
pubmed: 37236549
pii: S0002-9165(23)63950-4
doi: 10.1016/j.ajcnut.2023.05.026
pmc: PMC10447469
pii:
doi:
Substances chimiques
Glycated Hemoglobin
0
Blood Glucose
0
Banques de données
ClinicalTrials.gov
['NCT03336411']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-451Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL129953
Pays : United States
Organisme : NIMHD NIH HHS
ID : K99 MD012811
Pays : United States
Organisme : NIMHD NIH HHS
ID : R00 MD012811
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Informations de copyright
Copyright © 2023 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.
Références
Diabet Med. 2001 Jul;18(7):578-83
pubmed: 11553189
Obesity (Silver Spring). 2012 Jun;20(6):1234-9
pubmed: 21633403
N Engl J Med. 2003 May 22;348(21):2074-81
pubmed: 12761364
Am J Clin Nutr. 1990 Feb;51(2):241-7
pubmed: 2305711
Diabetes Care. 2008 Feb;31 Suppl 2:S150-4
pubmed: 18227477
Arch Intern Med. 2001 Feb 12;161(3):397-405
pubmed: 11176766
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E815-23
pubmed: 20071560
Diabetologia. 2009 Mar;52(3):415-24
pubmed: 19130039
Obes Rev. 2017 Jul;18(7):808-817
pubmed: 28524643
Curr Diabetes Rev. 2021;17(7):e071620183816
pubmed: 32674737
JAMA Netw Open. 2022 Sep 1;5(9):e2233760
pubmed: 36169954
Ann Intern Med. 2014 Sep 2;161(5):309-18
pubmed: 25178568
Am J Clin Nutr. 2019 Jul 1;110(1):63-75
pubmed: 31095300
JAMA. 2007 May 16;297(19):2092-102
pubmed: 17507345
Sci Rep. 2020 Jan 15;10(1):353
pubmed: 31941993
Trends Pharmacol Sci. 2020 Nov;41(11):868-881
pubmed: 32994049
Hepatology. 2002 Feb;35(2):373-9
pubmed: 11826411
Obesity (Silver Spring). 2010 Sep;18(9):1733-8
pubmed: 20019677
Curr Epidemiol Rep. 2018;5(4):432-441
pubmed: 30596004
Diabetes Care. 2021 Sep;44(9):1980-1991
pubmed: 34301736
J Diabetes Investig. 2021 May;12(5):886-893
pubmed: 32918856
Diabetes Care. 2023 Jan 1;46(Suppl 1):S97-S110
pubmed: 36507646
Diabetes Obes Metab. 2017 Feb;19(2):290-293
pubmed: 27761984
Contemp Clin Trials. 2021 Sep;108:106522
pubmed: 34352387
World J Mens Health. 2020 Jan;38(1):48-60
pubmed: 30929328
Diabetologia. 2014 Nov;57(11):2261-9
pubmed: 25208757
Ann Intern Med. 2004 May 18;140(10):769-77
pubmed: 15148063
EClinicalMedicine. 2021 Apr 25;35:100853
pubmed: 33997745
Int J Mol Sci. 2021 Aug 04;22(16):
pubmed: 34445099
Am J Clin Nutr. 2009 Jul;90(1):23-32
pubmed: 19439458
Diabetes Care. 2002 Dec;25(12):2165-71
pubmed: 12453955
JAMA. 2006 Apr 12;295(14):1681-7
pubmed: 16609090
JAMA Netw Open. 2019 Feb 1;2(2):e188102
pubmed: 30735238
JAMA. 2018 Feb 20;319(7):667-679
pubmed: 29466592
Appl Physiol Nutr Metab. 2021 Feb;46(2):148-154
pubmed: 32813987
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616
Cell. 2015 Nov 19;163(5):1079-1094
pubmed: 26590418
Nat Med. 2020 Jun;26(6):964-973
pubmed: 32528151
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
Lancet. 1999 Aug 21;354(9179):622-5
pubmed: 10466662
Contemp Clin Trials. 2019 Apr;79:80-88
pubmed: 30844471
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Diabetes Investig. 2018 Jul;9(4):713-725
pubmed: 29380542
Am J Epidemiol. 2003 Jun 15;157(12):1092-100
pubmed: 12796045